American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(suppl 1): S33-S50.
3.
Koro CE, Bowlin SJ, Bourgeois N, Fedder DO.Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27: 17-20.
4.
Saydah SH, Fradkin J, Cowie CC.Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA.2004;291: 335-342.
5.
Monnier L, Lapinski H, Colette C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care.2003;26: 881-885.
6.
Edelman SV, Weyer C.Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther.2002;4: 175-189.
7.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998;352: 837-853.
8.
Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD.Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA.1998;280: 140-146.
9.
Unger RH.Glucagon physiology and pathophysiology. N Engl J Med.1971;285: 443-449.
10.
Muller WA, Faloona GR, Aguilar-Parada E, Unger RH.Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med.1970;283: 109-115.
11.
Wahren J, Felig P, Hagenfeldt L.Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest.1976;57: 987-999.
12.
Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA.Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology.1995;109: 755-765.
13.
Horowitz M, Edelbroek MA, Wishart JM, Straathof JW.Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia.1993;36: 857-862.
14.
Phillips WT, Schwartz JG, McMahan CA.Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med.1992;33: 1496-1500.
15.
Nowak TV, Johnson CP, Wood CM, et al.Evidence for accelerated gastric emptying in asymptomatic patients with insulin-dependent diabetes mellitus. Gastroenterology.1990;98: A378-A378.
16.
Kruger DF, Gatcomb PM, Owen SK.Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25: 389-397.
17.
Symlin® (pramlintide acetate) injection [prescribing information]. San Diego, Calif: Amylin Pharmaceuticals Inc; 2005. Available at: http://symlin.com/pdf/SYMLIN-pi-combined.pdf. Accessed October 18, 2006.
18.
Kong M-F, Stubbs TA, King P, et al.The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia.1998;41: 577-583.
19.
Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.The human amylin analog, pramlintide, reduces postprandial hyper-glucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res.2002;34: 504-508.
20.
Fineman MS, Koda JE, Shen LZ, et al.The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism.2002;51: 636-641.
21.
Chapman I, Parker B, Doran S, et al.Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia.2005;48: 838-848.
22.
Hollander PA, Levy P, Fineman MS, et al.Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care.2003;26: 784-790.
23.
Ratner RE, Want LL, Fineman MS, et al.Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther.2002;4: 51-61.
24.
Maggs DG, Fineman M, Kornstein J, et al.Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev.2004;20: 55-60.
25.
Weyer C, Gottlieb A, Kim DD, et al.Pramlintide reduces post-prandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care.2003;26: 3074-3079.
26.
Whitehouse F, Kruger DF, Fineman M, et al.A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care.2002;25: 724-730.
27.
Ratner RE, Dickey R, Fineman M, et al.Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med.2004;21: 1204-1212.
28.
Edelman S, Garg S, Frias J, et al.A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care.2006;29: 2189-2195.
